After an average of 17 ± 2.3 weeks of PAH medication, the patients demonstrated an improvement in the 6-MWT (35 m on average) and a reduction in NT-proBNP (79 ng/L on average). This evidence concerns the gene NPPB and pulmonary arterial hypertension.